Noxopharm Ltd has released a press release.
Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Noxopharm August 2019 Corporate Presentation
- NOX Announces AU$26 Million Funding Facility
- Conference Hears of Positive Interim Data from LuPIN Trial
- Promising Data Leads to Expansion of LuPIN Trial
- LuPIN Trial Demonstrates High Rates of Response
Later from Noxopharm
- NOX Receives FY19 Federal Government R&D Tax Rebate
- More Evidence that Veyonda Enhances RT in Prostate Cancer
- Appendix 4E and Audited Financial Statements FY19
- Veyonda and Radiotherapy Profiled at Key Oncology Meeting
- Further Review Shows Major Clinical Benefits from Veyonda
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm